What are the indications for Mobosetinib/Mobosetinib?

Mobocertinib/Mobocertinib is an oral tyrosine kinase inhibitor , mainly used to target the wild type and mutant types of epidermal growth factor receptor (EGFR). Especially for patients with advanced or metastatic cancer who have developed drug resistance after intensive treatment, moboxetinib provides them with a new treatment option. It has significant specificity for EGFR exon 20 insertion mutations and is therefore mainly used clinically to treat non-small cell lung cancer (NSCLC).

Non-small cell lung cancer is the most common type of lung cancer, accounting for approximately 85% of all lung cancer cases. Among the many EGFR mutations, exon 20 insertion mutations are relatively rare, but they are an important reason why some patients develop resistance to traditional EGFR inhibitors (such as erlotinib, gefitinib, etc.). Therefore, the development of mobosetinib aims to provide an effective treatment option for these patients. Indications for its use are generally limited to patients whose disease has progressed despite first- or second-line treatment, such as platinum-based chemotherapy regimens and other EGFR inhibitors.

Mobosetinib is made under the brand nameExkivity and is available in 40 mg capsules. The recommended starting dosage is 160 mg orally once daily and may be adjusted based on patient tolerance. This treatment needs to be continued until disease progression or the patient develops unacceptable toxicity. In clinical application, although mobosetinib provides hope to patients, its side effects cannot be ignored. According to statistics, about half of patients need to interrupt the dose or reduce the dose by 25% during treatment, and 17% of patients even need to permanently discontinue the drug. Common adverse events include diarrhea, nausea, vomiting, decreased appetite, fatigue, pruritus, rash, paronychia, musculoskeletal pain, and stomatitis.

Reference materials:https://www.ncbi.nlm.nih.gov/books/NBK597509/